Which treatment strategy is NOT indicated for hyperkalemia in ESRD?

In patients with end-stage renal disease (ESRD) experiencing hyperkalemia, increasing potassium intake is contraindicated. Hyperkalemia, or elevated levels of potassium in the blood, poses serious health risks such as cardiac arrhythmias. In ESRD, the kidneys are severely impaired at excreting potassium, which often leads to elevated potassium levels.

Given this context, dietary management typically focuses on reducing potassium intake rather than increasing it. Administration of Kayexalate (sodium polystyrene sulfonate) and the use of diuretics may help lower potassium levels by promoting its excretion through the gastrointestinal tract or urine, respectively. Therefore, it is critical to avoid any strategies that would contribute to an increase in potassium levels, making the approach of increasing potassium intake not indicated in this scenario.